Background: Over the last decade, a new modality of immunotherapy has been announced, with the expectation of better long‐term clinical outcomes and disease‐free survival after the definitive surgical treatment of colon cancer. Natural killer (NK) cells as part of cellular therapy in immunotherapy have the potential effect as an adjuvant therapy for locally advanced and metastasized colorectal adenocarcinoma. We would evaluate the clinical outcome of autologous NK cell therapy for resectable colon cancer.Case: A 64‐year‐old woman presented with a transverse colon tumor‐related partial intestinal obstruction and a history of bloody diarrhea. A transverse colectomy has been done, and the pathology report reported adenocarcinoma of the transverse colon and positive lymph node involvement (TNM stage III). The patient had R0 resection status. A PET scan was done 6 months later, with positive lymph node glucose uptake at mesocolic. NK cell therapy was administered for 2 cycles with a 3‐month interval, and PET scan follow‐up was done 3 years after resection; no more glucose uptake was found, and the patients tolerated the therapy well with no immune‐related adverse effects reported.Conclusion: As a new modality in immunotherapy strategies for locally advanced colon adenocarcinoma, particularly in cases unsuitable for standard chemotherapeutic treatment, autologous NK cells have a promising effect and are feasible and well tolerated in our clinical practice.
As a diagnostic and therapeutic treatment role on malignant biliary obstruction, endoscopic retrograde cholangiopancreatography (ERCP) has already been used as a routine procedure, especially for palliative treatment on advanced stage peri-ampullary tumor. This minimal invasive procedure has many early or late complications such as bleeding, post-ERCP pancreatitis, perforation, cholangitis, and the rare duodenal perforation from the stent migration. The current review reported the incidence of stent erosion associated with duodenal perforation was only 1% for this palliative procedure. We report a 75 years old male patient with diffuse abdominal tenderness 7 days after palliative ERCP stent placement for malignant biliary obstruction, metal stent could not be placed, and plastic stent placement had been done. There was no post-ERCP pancreatitis found during the first 24 h. The patient came to the emergency with clinical sign and symptoms of diffuse peritonitis; abdominal X-ray found no free intraperitoneal air. Exploratory laparotomy was performed, and we found bile leak from the third part of perforated duodenal with 5 mm in diameter, plastic stent exposed from the perforation site, and no active bleeding. We performed primary suture of the duodenum, cholecysto-enteric bypass, pyloric exclusion, gastro-jejunostomy bypass, and braun anastomosis. Jejunostomy feeding has been placed. There were no postoperative cardiopulmonary complication, and the patient could tolerate well for oral intake and discharged from hospital at 10th postoperative day (POD). This rare duodenal perforation complication could happen even in plastic stent placement during the ERCP procedure, and early management was needed to gain the favorable outcome.
BACKGROUND: During our past 18 months, we must be faced with the current COVID-19 pandemic era with much uncertainty in the continuation of multimodality treatment of the gastrointestinal cancer patients. Especially in this immunocompromised group with the history of previous chemotherapy treatment, these patients have an increased risk of COVID-19 transmission. Many studies have been reported about the current recommendation for gastrointestinal cancer patients during this pandemic, but there might be a lack of evidence about the safety of vaccination for the gastrointestinal cancer patients. AIM: Since the vaccination has been approved by our government medical support, we would evaluate the safety of the COVID-19 vaccination program in gastrointestinal cancer patients. METHODS: All gastrointestinal cancer patients who have been already diagnosed with cancer will be included in this study. The vaccine-related sign symptoms will be recorded and evaluated. The chemotherapy schedule was not been interrupted following the vaccination. The patient who refused to receive the second vaccination dose will be excluded from this study. RESULTS: Thirty-two patients were included in this study (our past 6-month evaluation from February till August 2021), colorectal adenocarcinoma was the most common gastrointestinal cancer according to organ-specific (25 patients), the others were gastric adenocarcinoma, pancreatic adenocarcinoma, and small bowel gastrointestinal stromal tumor. Both of them already received two doses of COVID-19 vaccine during this period, we reported there was no side effect related to these and the chemotherapy cycle has not been interrupted during vaccination. All of the patients could be tolerated it well and did not refuse to continue the treatment. CONCLUSION: There were no significant signs and symptoms of vaccine-related side effects on gastrointestinal cancer patients. COVID-19 vaccination during this pandemic and following the chemotherapy schedule on any kind of gastrointestinal cancer patients was safe and could be suggested as a routine protocol.
4 January 2023 in Open Access Macedonian Journal of Medical Sciences
BACKGROUND: Surgical treatment of internal hemorrhoid is still challenging, short- and long-term clinical outcome were the most common issue. Chronic pain and recurrence case are the most common problem. Since it has been announced, HAL-RAR with Doppler guided is the treatment of choice, although it has economic issue on using this standard technique especially in the developing country which has limitation on health insurance. AIM: Using the same procedure as the standard HAL-RAR procedure and direct vision ligation, we hope that it could evaluate the clinical response of these modification technique on symptomatic Grade III of internal hemorrhoid cases. METHODS: We will evaluate the long-term clinical outcome of modified no Doppler guided technique on grade III of internal hemorrhoid cases. The inclusion criteria are the grade III of internal hemorrhoid, not associated with rectal cancer. A history of previous procedure or recurrence disease will be excluded from the study. Post-operative pain, 3 years recurrence disease, will be evaluated. RESULTS: We reported 65 patients, both of them have pain and bleeding. The procedure can be performed safely using direct vision and rectoscope. After 3 years, we reported there was no recurrence disease, no post-operative bleeding, and tolerable post-operative pain. We reported one case of chronic pain due to proctitis and could be managed conservatively. CONCLUSION: No Doppler-guided HAL-RAR was effective in controlling the post-operative pain, acceptable long-term clinical outcome with no recurrence.